Search

Search Results

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• KIR-Genetic Factors and Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

  Elena Vital’evna Kuzmich, I.E. Pavlova, L.N. Bubnova, S.S. Bessmeltsev

  119-127

  03.03.2023

• Asciminib in Chronic Myeloid Leukemia Patients Without Therapeutic Alternatives: Results of the MAP (Managed Access Program, NCT04360005) Trial in Russia

  A.G. Turkina, Elena Andreevna Kuzmina, E.G. Lomaia, E.V. Morozova, E.Yu. Chelysheva, O.A. Shukhov, A.N. Petrova, T.V. Chitanava, Yu.Yu. Vlasova, I.S. Nemchenko, A.V. Bykova, E.I. Sbityakova, M.A. Gurianova, N.N. Tsyba, A.V. Kokhno, E.N. Parovichnikova

  54-68

  01.01.2023

• Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Mai

  A.G. Turkina, Margarita Anatolevna Gurianova, E.Yu. Chelysheva, O.A. Shukhov

  54-61

  01.01.2022

• Biological Mechanisms of Sustaining Deep Molecular Response in Chronic Myeloid Leukemia Upon Withdrawal of Tyrosine Kinase Inhibitors

  Ekaterina Yurevna Chelysheva, M.A. Guryanova, A.G. Turkina

  427-435

  01.10.2021

• Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial

  Oleg Aleksandrovich Shukhov, A.N. Petrova, E.Yu. Chelysheva, A.V. Bykova, I.S. Nemchenko, A.G. Turkina

  1-12

  01.01.2021

• Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors

  Margarita Anatolevna Guryanova, E.Yu. Chelysheva, A.G. Turkina

  118-128

  01.01.2021

• Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)

  Ekaterina Yur’evna Chelysheva, A.G. Turkina, E.S. Polushkina, M.A. Vinogradova, R.G. Shmakov

  202-210

  01.04.2019

• Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)

  Oleg Aleksandrovich Shukhov, A.G. Turkina, E.Yu. Chelysheva, A.V. Bykova, A.N. Petrova, G.A. Gusarova, I.S. Nemchenko, A.O. Abdullaev, T.N. Obukhova, A.B. Sudarikov

  194-201

  01.04.2019

• Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice

  Anna Grigor’evna Turkina, N.V. Novitskaya, A.K. Golenkov, V.A. Shuvaev, L.I. Napso, I.V. Krylova, A.M. Savrilova, G.Sh. Safuanova, A.V. Korobkin, T.Yu. Klitochenko, E.V. Burnasheva, E.V. Vasil’ev, O.M. Senderova, E.Yu. Fedorova, L.M. Yalunina, E.K. Nekhai, G.B. Kuchma, A.S. Lyamkina, N.G. Shchedrova

  390-401

  01.07.2017

• First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors

  Vasilii Anatol’evich Shuvaev, K.M. Abdulkadyrov, I.S. Martynkevich, M.S. Fominykh

  78–83

  01.01.2015

• Current best options for first line treatment of chronic phase chronic myeloid leukemia

  R. Hehlmann, S. Saußele

  9-15

  01.01.2014